Multidrug resistance in leukemia

Current Opinion in Hematology

Volumn 5, Issue 4, 1998, Pages 287-291

  Leith, Catherine ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; HUMAN; LEUKEMIA; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

EID: 0032413898     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199807000-00008     Document Type: Review

References (53)

1. Juliano RL, Ling V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochem Biophys Acta 1976, 455:152-162.
2. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D: Clinical significance of multidrug resistance p-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1992, 79:473-476.
3. Guerci A, Merlin JL, Missoum N, Feldmann L, Marchal S, Witz F, Rose C, Guerci O: Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and p-glycoprotein expression simultaneously determined by flow cytometry. Blood 1995, 85:2147-2153.
4. Lamy T, Drenou B, Grulois I, Fardel O, Jacquelinet C, Goasguen J, Dauriac C, Amiot L, Bernard M, Fauchet R, Le Prise PY: Multi-drug resistance (MDR) activity in acute leukemia determined by rhodamine 123 efflux assay. Leukemia 1995, 9:1549-1555.
5. Musto P, Melillo L, Lombardi G, Matera R, Di Giorgio G, Carotenuto M: High risk of early resistant replase for leukaemic patients with presence of multidrug resistance associated p-glycoprotein positive cells in complete remission. Br J Haematol 1991, 77:50-53.
6. Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P, et al.: MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 1991, 83:708-712.
7. Wood P, Burgess R, MacGregor A, Liu JA: P-glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival. Br J Haematol 1994, 87:509-514.
8. Zochbauer S, Gsur A, Brunner R, Kryle PA, Lechner K, Pirker R: P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia. Leukemia 1994, 8:974-977.
9. Yuen AR, Sikic BI: Multidrug resistance in lymphomas. J Clin Oncol 1994, 12:2453-2459.
10. Grogan TM, Spier CM, Salmon SE, Matzner M, Rybski J, Weinstein RS, Scheper RJ, Dalton WS: P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993, 81:490-495.
11. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai S-L, Gazdar A, et al.: Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989, 81:116-124.
12. Goldstein LJ: MDR1 gene expression in solid tumours. Eur J Cancer 1996, 32A:1039-1050.
13. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W: Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 1993, 11:1652-1660.
14. List AF, Karanes C, Dorr R, Spier C, Grogan T, Greer J, et al.: Modulation of anthracycline resistance in poor-risk acute myeloid leukemia (AML) with SDZ PSC-833: results of a phase I/II multicenter study [abstract]. Blood 1996, 88:292a.
15. Marie JP, Bastie JN, Coloma F, Suberville AMF, Delmer A, Rio B, Delmas-Marsalet B, Leroux G, Casassus P, Baumelou E, Catalin J, Zittoun R: Cyclosporin A as a modifier agent in the salvage treatment of acute leukemia (AL). Leukemia 1993, 7:821-824.
16. Kornblau SM, Estey E, Madden T, Tran HT, Zhao S, Consoli U, et al.: Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol 1997, 15:1796-1802.
17. Sonneveld P, Schoester M, de Leeuw K: Clinical modulation of multidrug resistance in multiple myeloma: effect of cyclosporine on resistant tumor cells. J Clin Oncol 1994, 12:1584-1591.
18. Beck WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Kuttesch JF, et al.: Methods to detect p-glycoprotein-associated multidrug resistance in patient tumors: consensus recommendations. Cancer Res 1996, 56:3010-3020.
19. Marie JP: Editorial: debate round-table on phenotypic and genotypic analyses of multidrug resistance (MDR) in clinical hospital practice. Leukemia 1997, 11:1065-1066.
20. Pall G, Spitaler M, Hofmann J, Thaler J, Ludescher C: Multidrug resistance in acute leukemia: a comparison of different diagnostic methods. Leukemia 1997, 11:1067-1072.
21. Filipits M, Suchomel RW, Lechnier K, Pirker R. Immunocytochemical detection of the multidrug resistance-associated protein and p-glycoprotein in acute myeloid leukemia: impact of antibodies, sample source, and disease status. Leukemia 1997, 11:1073-1077. Evaluation of different antibodies in detection of MDR1 and MRP by immunohistochemistry are covered in this article. Fair or moderate correlations of results using different antibodies for MRP and MDR1 detection, respectively, are cited.
22. Den Boer ML, Zwaan CM, Pieters R, Rottier MMA, Flens MJ, Scheper RJ, Veerman AJP: Optimal immunocytochemical and flow cytometric detection of p-gp, MRP and LRP in childhood acute lymphoblastic leukemia. Leukemia 1997, 11:1078-1085. Nice study on the problems of evaluation of p-glycoprotein expression in acute lymphoblastic leukemia specimens using immunohistochemistry. Details on the effect of cell fixation, antibody batch, day-to-day variation in staining and interobserver reporting variation. A variation of up to 30% occurred when primary leukemic samples were stained on different days, or different observers interpreted the results. Presents suggested fixation methods for optimal staining.
23. Marie JP, Huet S, Faussat A-M, and the French Network of the Drug Resistance Intergroup. and Drug Resistance Network of Assistance Publique-Hopitaux de Paris: Multicentric evaluation of the MDR phenotype in leukemia. Leukemia 1997, 11:1086-1094. Multicenter study examining reproducibility of MDR1 detection on patient samples by flow cytometry. Includes detailed recommendations based on these studies for optimal detection of MDR1 by flow.
24. Chevillard S, Vielh PH, Validire P, and the French Network of the Drug Resistance Intergroup, and Drug Resistance Network of Assistance Publique-Hopitaux de Paris: French multicentric evaluation of mdr1 gene expression by RT-PCR in leukemia and solid tumours: standardization of RT-PCR and preliminary comparisons between RT-PCR and immunohistochemistry in solid tumours. Leukemia 1997, 11:1095-1106.
25. Beck WT, Grogan TM: Methods to detect p-glycoprotein and implications for other drug resistance-associated proteins. Leukemia 1997, 11:1107-1109.
26. Broxterman HJ, Lankelma J, Pinedo HM, Eekman CA, Währer DCR, Ossenkoppele GJ, Schuurhuis GJ: Theoretical and practical considerations for the measurement of p-glycoprotein function in acute myeloid leukemia. Leukemia 1997, 11:1110-1118. Summarizes this group's extensive experience examining p-glycoprotein function in AML using a variety of techniques. This group recommends a functional assay of MDR1 using the fluorescent dye, rhodamine-123, and the p-glycoprotein inhibitor, PSC 833. This paper gives significant detail both on theoretical and practical considerations for such tests in primary human leukemia samples.
27. Okochi E, Iwahashi T, Tsuruo T: Monoclonal antibodies specific for p-glycoprotein. Leukemia 1997, 11:1119-1123.
28. Petriz J, Garcia-Lopez J: Flow cytometric analysis of p-glycoprotein function using rhodamine 123. Leukemia 1997, 11:1124-1130.
29. Bosch J, Crankshaw CL, Piwnica-Worms D, Croop JM: Characterization of functional assays of multidrug resistance p-glycoprotein transport. Leukemia 1997, 11:1131-1137. Detailed discussion of setting up functional efflux experiments including the effects of different dyes and modulators on the results.
30. Krishan A, Sauerteig A, Andritsch I, Wellham L: Flow cytometric analysis of the multiple drug resistance phenotype. Leukemia 1997, 11:1138-1146. Detailed discussion of the use of different efflux drugs and blockers to optimally detect MDR1 functional activity.
31. Kuhnel JM, Perrot JY, Faussat AM, Marie JP, Schwaller MA: Functional assay of multidrug resistant cells using JC-1, a carbocyanine fluorescent probe. Leukemia 1997, 11:1147-1155. New dye method for MDR1 functional efflux. This method depends on change in color of a fluorochrome when it reaches a certain intracellular concentration. Potentially new and straightforward method to detect MDR1 activity.
32. Lampidis TJ, Shi Y-F, Calderon CL, Kolonias D, Tapiero H, Savaraj N: Accumulation of simple organic cations correlates with differential cytotoxicity in multidrug-resistant and -sensitive human and rodent cells. Leukemia 1997, 11:1156-1159.
33. Sonneveld P, Wiemer E: Assays for the analysis of P-glycoprotein in acute myeloid leukemia and CD34 subsets of AML blasts. Leukemia 1997, 11:1160-1165.
34. Dalton WS: Detection of multidrug resistance gene expression in multiple myeloma. Leukemia 1997, 11:1166-1169.
35. Morjani H, Millot J-M, Belhoussine R, Sebille S, Manfait M: Anthracycline subcellular distribution in human leukemia cells by microspectrofluorometry: factors contributing to drug-induced cell death and reversal of multidrug resistance. Leukemia 1997, 11:1170-1179.
36. Efferth T, Fabry U, Osieka R: Apoptosis and resistance to daunorubicin in human leukemic cells. Leukemia 1997, 11:1180-1186.
37. Leith CP, Chen I-M, Kopecky KJ, Appelbaum FR, Head DR, Godwin JE, Weick JK, Willman CL: Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant CD34+/MDR1-/Efflux+ and MDR1+/Efflux-cases. Blood 1995, 86:2329.
38. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak M, Chen I-M, Head DR, Appelbaum FR, Willman CL: Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study. Blood 1997, 89:3323-3329. Very large study (211 patients) of elderly AML patients enrolled on single clinical trial. Very high frequency of MDR1 expression (71%) in striking contrast to a frequency of 35% MDR1 expression in younger AML patients recently reported by the same group. Multivariate analysis showed CR rate was highly significantly and independently associated with MDR1 expression (P = 0.0041), secondary disease (P = 0.0035) and unfavorable cytogenetics (P = 0.0031). Resistant disease was highly significantly associated with MDR1 expression. There was no effect of MDR1 on overall or disease-free survival. These findings suggest that the differences in clinical response found in elderly compared to younger patients with AML may in part be related to differences in the biologic behavior of the disease.
39. Hunault M, Zhou D, Delmer A, Ramond S, Viguie F, Cadiou M, et al.: Multidrug resistance gene expression in acute myeloid leukemia: major prognosis significance for in vivo drug resistance to induction treatment. Ann Hematol 1997, 74:65-71. Large group of similarly though not uniformly treated patients. MDR1 found to be highly associated with CR rate. MRP also associated with CR rate. However, it was also strongly associated with MDR1 expression, so this may not be an independent factor for clinical response.
40. Leith CP, Kopecky KJ, Chen I-M, Slovak M, Head DR, Weick J, et al.: Frequency and clinical significance of expression of the multidrug resistance proteins, MDR1, MRP1, and LRP in acute myeloid leukemia patients less than 65 yrs old. Blood 1997, 90:389a. Frequency of MDR1, MRP, and LRP expression in 352 previously untreated patients with AML on single clinical trial. MDR1 was detected in 35%, MRP in 10%, and LRP in 43% of all cases. MDR1 but not MRP or LRP was associated with CR rates.
41. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, et al.: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992, 258:1650-1654.
42. Loe DW, Deeley RG, Cole SPC. Biology of the multidrug resistance-associated protein, MRP. Eu J Cancer 1996, 32A:945-957.
43. Schneider E, Cowan KH, Bader H, Toomey S, Schwartz GN, Karp JE, Burke PJ, Kaufman SH: Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 1995, 85:186-193.
44. Rosa DD, Doyle LA, Schiffer CA, Lee EJ, Grant CE, Cole SPC, Deeley RG, Yang W, Tong Y: Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients. Leukemia 1996, 10:48-55.
45. Schuurhuis GJ, Broxterman HJ, Ossenkoppele GJ, Baak JPA, Eekman CA, Kuiper CM, Feller N, can Heijningen THM, Klumper E, Pieters R, Lankelma J, Pinedo HM: Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-β-D-arabinofuranosylcytosine may predict clinical response in acute myeloid leukemia. Clin Cancer Res 1995, 1:81-93.
46. Hart SM, Ganeshaguuru K, Hoffbrand AV, Prentice HG, Mehta AB: Expression of the multidrug resistance-associated protein (MRP) in acute leukaemia. Leukemia 1994, 8:2163-2168.
47. Filipits M, Suchomel, RW, Zöchbauer S, Brunner R, Lechner K, Pirker R. Multidrug resistance-associated protein in acute myeloid leukemia: no impact on treatment outcome. Clin Cancer Res 1997, 3:1419-1425. A large clinical study (80 patients) examining the impact of MRP expression on clinical outcome. Patients were not treated with identical protocols but almost all (64 patients) received daunomycin plus standard-dose cytarabine with or without the addition of etoposide. MRP was detected at low (19%), intermediate (55%), or high levels (26%) in the 80 patients. No association between MRP expression and CR rate, overall survival, or disease-free survival. In contrast, high MDR1 expression was associated with decreased CR rate, OS and DFS.
48. Legrand O, Simonin G, Zittoun R, Marie J-P. Comparisons of MDR1, MRP and LRP expression with in vitro drug sensitivity and in vivo response to treatment in fresh blast cells from adult acute myeloid leukemia patients. Blood 1997, 90 (suppl 1):180a. MDR1 but not MRP or LRP expression is associated with differences in vitro drug sensitivity in AML blasts. Suggests that MDR1 expression may be the more important multidrug resistance protein.
49. Scheffer GL, Wijngaard PLJ, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJLM, Clever HC, Scheper RJ: The drug resistance-related protein LRP is the human major vault protein. Nature Med 1995, 1:578-582.
50. List AF, Spier CS, Grogan TM, Johnson C, Roe DJ, Greer JP, Wolff SN, Broxterman HJ, Scheffer GL, Scheper RJ, Dalton WS: Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 1996, 87:2464-2469.
51. Pirker R, Phol G, Stranzl T, Suchomel RW, Scheper RJ, Jäger U, Geissler K, Lechnier K, Filipits M: Expression of the lung resistance protein (LRP) predicts poor outcome in de novo acute myeloid leukemia. Blood 1997, 90(suppl 1):566a. Preliminary data suggesting that LRP expression highly correlated with clinical response (CR rate and overall survival) in AML. The discrepancy between these results and some others (see Leith et al., Blood 1997, 90 (suppl):389, is not explained at this time.
52. Pirker R, Phol G, Stranzl T, Suchomel RW, Scheper RJ, Jäger U, Geissler K, Lechnier K, Filipits M: Expression of the lung resistance protein (LRP) predicts poor outcome in de novo acute myeloid leukemia. Blood 1997, 90(suppl 1):566a. Preliminary data suggesting that LRP expression highly correlated with clinical response (CR rate and overall survival) in AML. The discrepancy between these results and some others (see Leith et al., Blood 1997, 90 (suppl):389, is not explained at this time.
53. Current Opinion in Hematology 1998, 5:292-301